Advertisement

Topics

ImaRx Therapeutics, Inc. Company Profile

22:20 EDT 19th September 2017 | BioPortfolio

At ImaRx, our goal is to improve patient outcomes by restoring critical bloodflow to organs such as the brain, heart, and lungs following acute ischemic or thrombotic events through our innovative technology and products.We are pursuing two development programs as the foundation for our products. The first program is a group of clot-dissolving drugs, or thrombolytics, that are variants of urokinase, a natural human protein primarily produced in the kidneys that stimulates the body’s natural clot-dissolving processes. The second program, SonoLysis therapy, centers on a novel treatment that breaks blood clots apart by applying ultrasound to submicron-sized bubbles, which we call SonoLysis bubbles. We believe these therapeutic approaches can be used either alone or in combination to treat ischemic stroke and a broad variety of vascular disorders associated with blood clots, and may expand the number of patients for whom safe and effective clot-dissolving therapies are available

Location

1635 East 18th Street
Tucson
Arizona
85719
United States of America

Contact

Phone: (520) 770-1259
Fax: (520) 791-2437
Email: imarx@imarx.com


News Articles [1517 Associated News Articles listed on BioPortfolio]

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...

Summit Therapeutics PLC (SMMT) and Orexigen Therapeutics (OREX) Head to Head Review

Summit Therapeutics PLC and Orexigen Therapeutics are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, in...

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...

M&As this week: Bioverativ Therapeutics, Horizon Pharma

Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics.

Dragonfly Therapeutics names world leader in NK therapeutics as CSO

Dragonfly Therapeutics has appointed Nicolai Wagtmann as its chief scientific officer (CSO).

Head-To-Head Survey: Anika Therapeutics (ANIK) versus Its Peers

Anika Therapeutics is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it compare to its competitors? We will compare Anika Therapeutics to related companies based on the ...

Clinical Trials [116 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1145 Associated Companies listed on BioPortfolio]

ImaRx Therapeutics, Inc.

At ImaRx, our goal is to improve patient outcomes by restoring critical bloodflow to organs such as the brain, heart, and lungs following acute ischemic or thrombotic events through our innovative tec...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "ImaRx Therapeutics, Inc." on BioPortfolio

We have published hundreds of ImaRx Therapeutics, Inc. news stories on BioPortfolio along with dozens of ImaRx Therapeutics, Inc. Clinical Trials and PubMed Articles about ImaRx Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImaRx Therapeutics, Inc. Companies in our database. You can also find out about relevant ImaRx Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record